A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Insomnia Disorder
Interventions
DRUG

Daridorexant

Daridorexant will be taken orally, once daily in the evening as indicated by investigator.

DRUG

Placebo

Placebo will be taken orally, once daily in the evening as indicated by investigator.

Trial Locations (17)

10380

Inje University Ilsan Paik Hospital, Ilsan

13620

Seoul National University Bundang Hospital, Seongnam-si

16247

The Catholic University of Korea, ST. Vincent's Hospital, Suwon

21565

Gachon University Gil Medical Center, Incheon

22711

Catholic Kwandong University International St. Mary'S Hospital, Incheon

26426

Wonju Severance Christian Hospital, Wŏnju

31151

Soon Shun Hyang University Cheonan Hospital, Cheonan

35015

Chungnam National University Hospital, Daejeon

42601

Keimyung University Dongsan Medical Center, Daegu

47392

Inje University Busan Paik Hospital, Busan

50612

Pusan National University Yangsan Hospital, Busan

61469

Chonnam National University Hospital, Gwangju

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05278

Kyung Hee University Hospital At Gangdong, Seoul

05505

Asan Medical Center, Seoul

07804

Ewha Womans University Medical Center, Seoul

All Listed Sponsors
lead

Nxera Pharma Korea Co., Ltd.

INDUSTRY

NCT07028697 - A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder | Biotech Hunter | Biotech Hunter